Pfizer’s innovative nasal spray, Zavzpret, has received Food and Drug Administration’s (FDA) approval for migraine treatment. This medication utilizes a unique therapy approach that is safer for individuals at risk of heart attacks or strokes, as compared to other nasal products available for severe headache pain.  

According to clinical trial results published in Lancet Neurology, Zavzpret has been shown to be more effective than a placebo in relieving pain and alleviating patients’ most bothersome symptoms, with a quick return to normal function within 30 minutes to two hours after administration. Zavzpret is slated to hit pharmacy shelves in July, although uncertainties remain about access to the medication.